SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Schaefer Thomas J.

(Last) (First) (Middle)
C/O ARCADIA BIOSCIENCES
202 COUSTEAU PLACE, SUITE 105

(Street)
DAVIS CA 95618

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/03/2023
3. Issuer Name and Ticker or Trading Symbol
Arcadia Biosciences, Inc. [ RKDA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 2,100 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (1) 07/27/2030 Common Stock 8,000 3.67 D
Stock Option (Right to Buy) (2) 01/21/2031 Common Stock 4,000 3.05 D
Stock Option (Right to Buy) (3) 10/01/2031 Common Stock 20,000 2.09 D
Stock Option (Right to Buy) (4) 04/11/2032 Common Stock 23,000 1.27 D
Stock Option (Right to Buy) (5) 04/11/2032 Common Stock 31,000 1.27 D
Stock Option (Right to Buy) (6) 08/16/2032 Common Stock 23,000 0.94 D
Explanation of Responses:
1. The options were granted on 7/27/2020 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.
2. The options were granted on 1/21/2021 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.
3. The options will vest monthly in equal installments over a period of four years from the date of the grant, 10/1/2021, subject to the Participant's continued service.
4. The options will vest annually in equal installments over a period of two years from the date of the grant, 4/11/2022, subject to the Participant's continued service.
5. The options were granted on 4/11/2022 and the vesting occurs as follows, subject to the Participant's continued service: (1) 25% of the shares vest on the first anniversary of the date of the award and (2) 75% of the shares vest in 36 equal installments, the first installment occurring on the last day of the month in which the initial vesting date occurs.
6. The options will vest annually in equal installments over a period of three years from the date of the grant, 8/16/2022, subject to the Participant's continued service.
Remarks:
Thomas Schaefer, by Attorney-in-fact, Solaeta Chan 01/05/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

       Know all by these presents, that the undersigned hereby constitutes and
appoints each of Pamela Haley and
Solaeta Chan, signing singly, the undersigned's true and lawful attorney-in-fact
to:

(i)	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director of
Arcadia Biosciences, Inc. (the "Company"), Forms 3, 4 and 5  (including
amendments thereto), and for the
purpose of filing such Forms, to execute and deliver any documents necessary to
the Securities and
Exchange Commission ("SEC") for the purpose of obtaining EDGAR codes, all in
accordance with Section
16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and the rules and
regulations promulgated thereunder;

(ii)	do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to
complete and execute any such Forms 3, 4 or 5 and timely file such form
(including amendments thereto)
with the SEC and any stock exchange or similar authority; and

(iii)	take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such
attorney-in-fact, may be of benefit to, in the best interest of, or legally
required by the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to
this Power of Attorney shall be in such form and shall contain such terms and
conditions as such attorney-
in-fact may approve in such attorney-in-fact's discretion.

       The undersigned hereby grants to such attorney-in-fact full power and
authority to do and perform any and
every act and thing whatsoever requisite, necessary or proper to be done in the
exercise of any of the rights and
powers herein granted, as fully to all intents and purposes as the undersigned
might or could do if personally present,
with full power of substitution and revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney
and the rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming nor
is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.

       The undersigned agrees that such attorney-in-fact may rely entirely on
information furnished orally or in
writing by the undersigned to such attorney-in-fact.  The undersigned also
agrees to indemnify and hold harmless
the Company and such attorney-in-fact against any losses, claims, damages or
liabilities (or actions in these
respects) that arise out of or are based on any untrue statement or omission of
necessary facts in the information
provided by the undersigned to such attorney-in-fact for purposes of executing,
acknowledging, delivering and filing
Forms 3, 4 or 5 (including amendments thereto) and agrees to reimburse the
Company and such attorney-in-fact for
any legal or other expenses reasonably incurred in connection with investigating
or defending against any such loss,
claim, damage, liability or action.

       This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to
file Forms 3, 4 or 5 with respect to the undersigned's holdings of and
transactions in securities issued by the
Company, unless earlier (a) revoked by the undersigned in a signed writing
delivered to the foregoing attorney-in-
fact or (b) superseded by a new power of attorney regarding the purposes
outlined in the first paragraph hereof as of
a later date.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 6th day of December, 2022.


	Signature:				/s/ Thomas J. Schaefer